Literature DB >> 18691273

Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis.

Stefano Palomba1, Renato Pasquali, Francesco Orio, John E Nestler.   

Abstract

BACKGROUND: To date, no systematic review or meta-analysis has been published of direct head-to-head studies comparing clomiphene citrate (CC) vs. metformin, or the combination of both drugs as first-line therapy in anovulatory polycystic ovary syndrome (PCOS) patients seeking pregnancy. The aim of the current paper was to define, if possible, the best evidence-based recommendations regarding the use of CC and/or metformin as the initial treatment of PCOS women with anovulatory infertility.
DESIGN: Systematic review and meta-analysis of the head-to-head randomized controlled trials (RCTs) available in the literature.
METHODS: A bibliographic search was performed using the following bibliographic databases: Medline, EMBASE, Biological Abstracts, Cochrane Controlled Trials Register and Cochrane Database of Systematic Reviews. Reference lists of included studies, other relevant review articles and textbooks were checked for additional citations of interest.
RESULTS: Four head-to-head RCTs were identified and qualified for inclusion in the analysis. No difference in fertility improvement was observed comparing CC with metformin (OR = 1.22, 95% CI 0.23-6.55, P = 0.815), whereas a significant (P < 0.0001) heterogeneity was observed. Homogeneous data showed no difference in fertility improvement between the combination treatment and CC monotherapy (OR = 0.99, 95% CI 0.70-1.40, P = 0.982), but a significant difference in comparison with metformin monotherapy (OR = 0.23, 95% CI 0.14-0.37, P < 0.0001).
CONCLUSIONS: In PCOS patients with anovulatory infertility and not previously treated, the administration of metformin plus CC is not better than monotherapy (metformin alone or CC alone), whereas to date no specific recommendation can be given regarding the use of CC or metformin as first-step drug.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18691273     DOI: 10.1111/j.1365-2265.2008.03369.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  27 in total

Review 1.  Fertility treatment in women with polycystic ovary syndrome: a decision analysis of different oral ovulation induction agents.

Authors:  Emily S Jungheim; Anthony O Odibo
Journal:  Fertil Steril       Date:  2010-05-07       Impact factor: 7.329

Review 2.  Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome.

Authors:  Selma F Witchel; Sergio E Recabarren; Frank González; Evanthia Diamanti-Kandarakis; Kai I Cheang; Antoni J Duleba; Richard S Legro; Roy Homburg; Renato Pasquali; Rogerio A Lobo; Christos C Zouboulis; Fahrettin Kelestimur; Franca Fruzzetti; Walter Futterweit; Robert J Norman; David H Abbott
Journal:  Endocrine       Date:  2012-06-04       Impact factor: 3.633

Review 3.  Why AMPK agonists not known to be stressors may surprisingly contribute to miscarriage or hinder IVF/ART.

Authors:  Elizabeth E Puscheck; Alan Bolnick; Awoniyi Awonuga; Yu Yang; Mohammed Abdulhasan; Quanwen Li; Eric Secor; Erica Louden; Maik Hüttemann; Daniel A Rappolee
Journal:  J Assist Reprod Genet       Date:  2018-06-07       Impact factor: 3.412

Review 4.  Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.

Authors:  Lara C Morley; Thomas Tang; Ephia Yasmin; Robert J Norman; Adam H Balen
Journal:  Cochrane Database Syst Rev       Date:  2017-11-29

5.  Metformin use in patients undergoing in vitro fertilization treatment: results of a worldwide web-based survey.

Authors:  Mindy S Christianson; Harold Wu; Yulian Zhao; Matan Yemini; Milton Leong; Zeev Shoham
Journal:  J Assist Reprod Genet       Date:  2015-01-30       Impact factor: 3.412

6.  Commonly used fertility drugs, a diet supplement, and stress force AMPK-dependent block of stemness and development in cultured mammalian embryos.

Authors:  Alan Bolnick; Mohammed Abdulhasan; Brian Kilburn; Yufen Xie; Mindie Howard; Paul Andresen; Alexandra M Shamir; Jing Dai; Elizabeth E Puscheck; Daniel A Rappolee
Journal:  J Assist Reprod Genet       Date:  2016-05-26       Impact factor: 3.412

7.  Two-cell embryos are more sensitive than blastocysts to AMPK-dependent suppression of anabolism and stemness by commonly used fertility drugs, a diet supplement, and stress.

Authors:  Alan Bolnick; Mohammed Abdulhasan; Brian Kilburn; Yufen Xie; Mindie Howard; Paul Andresen; Alexandra M Shamir; Jing Dai; Elizabeth E Puscheck; Eric Secor; Daniel A Rappolee
Journal:  J Assist Reprod Genet       Date:  2017-09-15       Impact factor: 3.412

Review 8.  Current knowledge of obesity's effects in the pre- and periconceptional periods and avenues for future research.

Authors:  Emily S Jungheim; Kelle H Moley
Journal:  Am J Obstet Gynecol       Date:  2010-08-24       Impact factor: 8.661

9.  Role of metformin in the management of polycystic ovary syndrome.

Authors:  Hany Lashen
Journal:  Ther Adv Endocrinol Metab       Date:  2010-06       Impact factor: 3.565

Review 10.  Metformin use in women with polycystic ovary syndrome.

Authors:  Neil P Johnson
Journal:  Ann Transl Med       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.